National disability insurance scheme access: What evidence do you need to provide for psychosocial disability?

access evidence implementation national disability insurance scheme psychosocial disability

Journal

Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists
ISSN: 1440-1665
Titre abrégé: Australas Psychiatry
Pays: England
ID NLM: 9613603

Informations de publication

Date de publication:
04 2023
Historique:
medline: 11 4 2023
pubmed: 9 2 2023
entrez: 8 2 2023
Statut: ppublish

Résumé

The National Disability Insurance Scheme (NDIS) was introduced in 2013 and offered a new way of providing support to people with permanent and significant disabilities. Despite pilot testing, implementation of the scheme has been challenging, particularly for people with a disability arising from a mental health condition. In 2019, to address the challenge of accessing the NDIS, researchers from Flinders University worked with the National Disability Insurance Agency (NDIA) to develop a streamlined access process for psychosocial disability. The aim of this paper is to provide guidance on the evidence required to demonstrate that a person has a significant and persistent psychosocial disability to access the NDIS. Providing evidence for a psychosocial disability requires knowledge of how to address the disability requirements. The Evidence of Psychosocial Disability (EPD) form has been designed to address these requirements and offers guidance on the evidence that should be provided. A range of resources to accompany the EPD form are freely available online. These resources address a significant knowledge gap that currently exists with the implementation of the NDIS.

Identifiants

pubmed: 36752271
doi: 10.1177/10398562231154117
pmc: PMC10088339
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

174-177

Références

Aust N Z J Psychiatry. 2001 Oct;35(5):677-83
pubmed: 11551285
Health Soc Care Community. 2021 Sep;29(5):1378-1390
pubmed: 33051906
J Law Med. 2020 Dec;28(1):145-164
pubmed: 33415897

Auteurs

Tania Shelby-James (T)

Principal Research Fellow, College of Medicine & Public Health, 1065Flinders University, Adelaide, Australia.

Amy Duncan (A)

Research Fellow, College of Medicine & Public Health, 1065Flinders University, Adelaide, Australia.

Megan Rattray (M)

Research Fellow, College of Medicine & Public Health, 1065Flinders University, Adelaide, Australia.

Richard Reed (R)

Professor General Practice, College of Medicine & Public Health, 1065Flinders University, Adelaide, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH